Loading...
•
Jun 30, 2021
Adaptive Biotechnologies Q2 2021 Earnings Report
Reported an 83% increase in revenue compared to the second quarter of the prior year.
Key Takeaways
Adaptive Biotechnologies reported a strong second quarter with significant revenue growth, driven by sequencing and development revenue. The company is also making progress in its immune medicine platform, with emerging data expected to monetize for multiple opportunities.
Revenue of $38.5 million for the second quarter 2021, representing an 83% increase from the second quarter 2020
clonoSEQ clinical sequencing volume in the second quarter 2021 grew 75% versus prior year and 15% over the first quarter of 2021
Signed a license agreement with Vaccibody to leverage Adaptive Biotechnologies’ T-cell data to inform the development of a T-cell based SARS-CoV-2 vaccine
Signed an agreement with Moderna to use immunoSEQ T-MAP COVID to measure the T-cell response to their second generation COVID vaccine and their Zika vaccine
Forward Guidance
Adaptive Biotechnologies expects full year 2021 revenue to be in the range of $148 million to $155 million, representing 54% growth at the mid-point of the range over full year 2020 revenue. This compares to Adaptive Biotechnologies’ previous outlook of $145 million to $155 million.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...